Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients

Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025

Read more at globenewswire.com